CD4(+) CD28(+) lymphocytes on day 5 after high-dose melphalan for multiple myeloma predict a low risk of infections during severe neutropenia and are associated with the number of reinfused T lymphocytes of the autologous stem cell graft

Cytotherapy. 2011 Sep;13(8):987-92. doi: 10.3109/14653249.2011.579960. Epub 2011 May 23.

Abstract

Background aims: Neutropenia following high-dose chemotherapy is associated with a substantial risk of infectious complications. The aim of this study was to identify variables in residual leukocyte subsets during neutropenia that are predictive for neutropenic fever.

Methods: Residual leukocytes in the peripheral blood on day 5 after autologous blood stem cell transplantation were analyzed by three-color flow cytometry in 55 consecutive patients with multiple myeloma. Furthermore, the number of T cells transfused with the autografts was determined.

Results: Neutrophil counts at day 5 and neutrophil engraftment were similar in patients with and without neutropenic fever. Low absolute lymphocyte, CD4(+) CD28(+) and CD45RO(+) CD28(+) counts at day 5 were associated with neutropenic fever. T-cell counts at day 5 correlated with the CD3(+) cell number in the graft.

Conclusions: Our data show that the absolute lymphocyte, CD4(+) CD28(+) and CD45RO(+) CD28(+) counts play a role in host defense during severe neutropenia. The T-cell number in the graft may help to identify patients at high risk of neutropenic infections.

MeSH terms

  • Aged
  • CD28 Antigens / biosynthesis
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism*
  • CD4-Positive T-Lymphocytes / pathology
  • CD4-Positive T-Lymphocytes / transplantation
  • Cell Count
  • Female
  • Humans
  • Immunophenotyping
  • Infections / diagnosis*
  • Infections / etiology
  • Infections / pathology
  • Infections / therapy*
  • Male
  • Melphalan / administration & dosage*
  • Melphalan / adverse effects
  • Middle Aged
  • Multiple Myeloma / complications
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / pathology
  • Multiple Myeloma / therapy*
  • Neutropenia / etiology
  • Prognosis
  • Prospective Studies
  • Risk
  • Stem Cell Transplantation*
  • Transplantation, Autologous

Substances

  • CD28 Antigens
  • Melphalan